Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder
A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder
Sponsor: Otsuka Beijing Research Institute
This PHASE3 trial investigates Autistic Disorder and is currently completed. Otsuka Beijing Research Institute leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
Status: Enrolling By Invitation → Completed
-
Aug 2020 — Jan 2021 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2020 — Aug 2020 [monthly]
Enrolling By Invitation PHASE3
Status: Recruiting → Enrolling By Invitation
▶ Show 4 earlier versions
-
Mar 2019 — Feb 2020 [monthly]
Recruiting PHASE3
-
Oct 2018 — Mar 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Otsuka Beijing Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .